Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Study Finds Cilostazol Better Than Aspirin After Stroke

This article was originally published in PharmAsia News

Executive Summary

Chinese researchers have determined cilostazol, an anti-clotting drug, may be safer than aspirin for some people who have had a stroke. Such patients are considered at higher risk of a cerebral hemorrhage, but the anti-platelet drug appears to have a long-term effect in low doses. The researchers' work was published online by the journal The Lancet Neurology. Cilostazol is made in China by Otsuka Pharmaceutical under the brand Pletal. (Click here for more

You may also be interested in...

Otsuka Signs On To Promote Two UCB Products Just In Time For Possible Raised Safety Concerns

Otsuka and UCB have agreed to a co-development and co-promotional deal for the Belgium firm's antiepileptic Keppra (levetiracetam) and anti-TNF alpha drug Cimzia (certolizumab pegol) for the Japanese market while both products currently face potential safety hurdles in the U.S

Trump's Order For US Agencies To 'Buy American' Essential Medicines Has China Bracing For Impact

Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.

Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?

Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts